



FORM PTO - 1449 ATTORNEY DOCKET NO.: WYE-014 O'Toole et al. APPLICANT(S): SUPPLEMENTAL SERIAL NO.: 10/718,834 INFORMATION DISCLOSURE STATEMENT FILING DATE: November 21, 2003 **GROUP NO.:** 1646 **U.S. PATENT DOCUMENTS** SUB FILING DATE IF DOCUMENT EXAM. APPROPRIATE INIT. NUMBER DATE NAME CLASS CLASS FOREIGN PATENT DOCUMENTS **ENGLISH** COUNTRY SUB FILING **ABSTRACT** LANG EXAM. DOCUMENT CLASS CLASS DATE ONLY (Y/N) NUMBER DATE CODE INIT. N DG Bl WO 02/059260 08/01/02 wo OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. Database Geneseq Online 25 February 2003 (2003-02-25), "Human protein SEQ ID 521," Cl DG XP002350892, retrieved from EBI accession no. GSN: ABP64861 Database accession no. ABP64861. Database UniProt Online 1 May 2000 (2000-05-01), XP002350893 retrieved from EBI Database C2 DG accession no. Q9VFS6. Database UniProt Online 1 March 2003 (2003-03-01), XP002350894 retrieved from EBI Database C3 DG accession no. O8CHT3. European Search Report for Application Number 03786989.8 (PCT/US03/37317) dated November 11, C4 DG 2005, 5 pages. Vilella-Bach et al., "The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-C5 associated Protein Kinase Activity and G1 Progression," Journal of Biological Chemistry, DG 274(7):4266-4272 (1999). /Daniel Gamett/ (09/20/2006) DATE CONSIDERED **EXAMINER**

MAR 2 9 2003 3245

Complete if Known Substitute for form 1449A/PTO 10/718,834 Application Number INFORMATION DISCLOSURE November 21, 2003 Filing Date STATEMENT BY APPLICANT Margot O'Toole et al. First Named Inventor (use as many sheets as necessary) 1646 Art Unit Unassigned Examiner Name Attorney Docket Number 031896-091000 Sheet 1

| U.S. PATENT DOCUMENTS | | | | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|--|--|--|
| Examiner Initials | Cite No. ¹ | U.S. Patent Document Number - Kind Code ³ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | | |
| | | US- | | | | | | |
| | 1 | US- | | | | | | |
| | | US- | | | | | | |
| | | US- | | | | | | |

| | | FO | REIGN PATENT DO | DCUMENTS | | | |
|------------------------|--------------------------|--|--------------------------------|--|---|----|--|
| Examiner . Initials | Cite No. ¹ | Foreign Patent Document Kind Code ³ Country Code ³ Number ⁴ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Application of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T* | |
| | | | | | | | |
| | | OTHER PRIOR A | rt – non patent l | ITERATURE DOCUMENTS | | | |
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | | |
| DG | | PCT International Search Report; PCT/US03/37317; mailed January 6, 2005, 6 pages | | | | | |
| DG | | BALOW ET AL., New Prospects For Treatment of Lupus Nephritis, SEMINARS IN NEPHROLOGY, Vol. 20, No. 1, pgs. 32-39, 2000 | | | | | |
| DG | | DAVIS ET AL., Lupus Nephritis, Current Opinion in Rheumatology, Vol. 8, No. 5, pgs. 415-423, 1996 | | | | | |
| DG | | MERCADAL ET AL., Lupus Nephritis, A Review of the Current Pharmacological Treatments, EXPERT OPINION PHARMACOTHER., Vol. 5, No. 11, pgs. 2263-2277, 2004 | | | | | |
| DG | | RAHMAN ET AL., A Novel Susceptibility Locus On Chromosone 2 in the (New Zealand Black x New Zealand White) F ₁ Hybrid Mouse Model of Systematic Lupus Erythematosus, The JOURNAL OF IMMUNOLOGY, Vol. 168, No. 6, pgs. 3042-3049, 2002 | | | | | |
| DG | | BP TSAO, Genetic Susceptibility to Lupus Nephritis, LUPUS, Vol. 7, No. 9, pgs. 585-590, 1998 | | | | | |

| Examiner Signature | /Daniel Gamett/ | (09/20/2006) | Date Considered | |
|-----------------------|-----------------|--------------|--------------------|--|
| | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.